16 results about "Therapy HIV" patented technology

The invention belongs to the technical field of medicines, and particularly relates to pyrrolo [2, 3-d] pyrimidine compounds of aryl fragments and piperidine fragments as well as a preparation method and application of the pyrrolo [2, 3-d] pyrimidine compounds. The pyrrolo [2, 3-d] pyrimidine compound containing the aryl fragment and the piperidine fragment is an HIV-1 reverse transcriptase inhibitor, and the pyrrolo [2, 3-d] pyrimidine compound further comprises pharmaceutical salt, hydrate and solvate of the pyrrolo [2, 3-d] pyrimidine compound, polycrystal or eutectic of the pyrrolo [2, 3-d] pyrimidine compound, and precursors and derivatives with the same biological functions of the pyrrolo [2, 3-d] pyrimidine compound. The invention also relates to a preparation method of the compound and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

The invention relates to the technical field of biological medicines, in particular to an injection for treating AIDS and a preparation method thereof. The extraction method of the sulfate algae polysaccharide comprises the following steps: mixing seaweed meal, cellulase and water, carrying out enzymolysis, and extracting for 10-12 hours to obtain an extract; filtering, adding magnesium chloride hexahydrate into filtrate, standing for 20-30 minutes, centrifuging, taking supernatant, removing impurities, adding absolute ethyl alcohol until the final concentration is 55-65%, and precipitating polysaccharide; and purifying the precipitated crude polysaccharide, and freeze-drying to obtain the sulfate algae polysaccharide. The purity of the sulfate algae polysaccharide is greater than or equal to 95%, and the sulfate algae polysaccharide is cooperated with lentinan to obtain a safe and stable injection with an excellent treatment effect on AIDS (Acquired Immune Deficiency Syndrome). And a new scheme is provided for treatment of AIDS.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)—or the like; each R1 independently represents a halogen atom or the like; each of R1a and R1b independently represents a hydrogen atom or the like, R2represents an alkyl group or a haloalkyl group, R3represents a hydrogen atom or an alkyl group; and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof; and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection. (Formula (I))

The application discloses application of a PHD3 inhibitor in prevention and treatment of AIDS. Through immunological, biochemical and other multidisciplinary research means, the application analyzes the mechanism that a viral antisense protein ASP inhibits production of type I IFN to realize immune escape and establish latent infection in an HIV-1 infection process. Mechanically, after being expressed into a protein in a cell in the body, the ASP needs to undergo post-translational modification to exert its inhibiting effect, and after hydroxylation modification of a 47-position proline, the ASP can help to realize the ability of inhibiting the body immune response, and the post-translational modification depends on a host proline hydroxylase 3 (PHD3) to realize. Based on the mechanism-based research, it is found that a PHD3 inhibitor Molidustat offsets the hydroxylation of the ASP by PHD3, thereby blocking the immune evasion of HIV-1 and antagonizing infection, and showing a good development prospect of an AIDS treatment and prevention drug.

The present disclosure provides a composition for treating a viral infection. In one aspect, the present disclosure provides a composition for treating a viral infection in a subject, the composition containing a nucleic acid construct containing, in an operable manner, a nucleic acid sequence encoding an antigen protein contained in a virus belonging to the genus Lentivirus or a part thereof and a nucleic acid sequence encoding Ag85B protein. In one embodiment, the composition of the present disclosure is administered after the viral infection.

This invention belongs to the field of pharmaceutical technology, specifically relating to a pyrimidine cyclic compound containing deuterated methyl groups, its preparation method, and its uses. The compound structure of this invention is shown in general formula I, and also includes its pharmaceutical salt, hydrate, and solvate, its polycrystalline or cocrystalline forms, and its precursors and derivatives with similar biological functions. This compound or its composition can be used to prepare drugs for the prevention or treatment of AIDS and related diseases. In vitro cellular level anti-HIV-1 activity experiments show that this type of small molecule has strong anti-HIV-1 biological activity, significantly inhibiting viral replication in HIV-1-infected MT-4 cells, and exhibiting low cytotoxicity.

This invention belongs to the field of pharmaceutical technology, specifically relating to heteroarylpyrimidine derivatives containing a pyridine-benzene ring structure, their preparation methods, and uses. The compounds of this invention are heteroarylpyrimidine derivatives containing a pyridine-benzene ring structure, and also include their pharmaceutical salts, hydrates, and solvates, as well as their polycrystalline or cocrystalline forms, and their precursors and derivatives with similar biological functions. These compounds or combinations thereof can be used to prepare drugs for the prevention or treatment of AIDS and related diseases. In vitro cellular level anti-HIV-1 activity experiments show that these small molecules possess strong anti-HIV-1 biological activity, significantly inhibiting viral replication in HIV-1-infected MT-4 cells, and exhibiting low cytotoxicity.

The use of EN219 in the preparation of a drug for preventing and treating AIDS. The present application confirms that EN219 can promote the function of innate immune cells, disrupt the immune escape strategy of HIV, and inhibit the replication of HIV in immune cells. The present application overcomes, to a certain extent, the drawback of high medication adherence required by traditional AIDS treatment drugs, discovers a new host drug target, and has brand-new application prospects.

Compositions and methods for inhibiting HIV protease are disclosed. The compositions include an extract from Cassia acutifolia stems, or a fraction thereof, alone or in a pharmaceutically acceptable carrier. The extracts can be obtained by subjecting Cassia acutifolia pulverized stems to methanol / dichloromethane (1:1) extraction. In a first extraction stage, Cassia acutifolia pulverized stems are macerated in a mixture of methanol / dichloromethane. In a second stage methanol is added to the remaining marc vortex and extracted for a suitable time period at room temperature. The extract from the first and second stages are combined. The extracts can be further processed for formulation into a suitable pharmaceutical form.

The invention belongs to the technical field of medicines, and particularly relates to a dihydropyridino [3, 4-D] pyrimidine compound as well as a preparation method and application thereof. The dihydropyrido [3, 4-D] pyrimidine compound disclosed by the invention is an HIV-1 (human immunodeficiency virus-1) non-nucleoside reverse transcriptase inhibitor. The invention also discloses pharmaceutical salts, hydrates, solvates, polycrystals or co-crystals of the compounds, precursors and derivatives with the same biological functions of the compounds, a preparation method of the compounds and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. An in-vitro cellular level anti-HIV-1 activity experiment result shows that the small molecule compound has relatively strong anti-HIV-1 activity, can effectively inhibit the replication of HIV-1 viruses in MT-4 cells infected by the HIV-1 viruses, and has relatively low cytotoxicity.

The present disclosure relates generally to compounds of Formula I represented below: [Image disponible dans le document PDF, Image available in the PDF document] The present disclosre also relates to pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

The purpose of the present invention is to provide a medicine useful for treating HIV infection by using compounds having different mechanisms in combination with kick and kill therapy. A medicine characterized by being a combination of (A) a polynucleotide or polypeptide that induces an anti-HIV Tat antibody that inhibits the activity of HIV Tat protein secreted from HIV-infected cells, and (B) a pattern recognition receptor agonist that induces type I IFN, is useful for the treatment, etc., of HIV infection.